C-mannoside compounds useful for the treatment of urinary tract infections
Disclosed herein are C-mannoside compounds, compositions thereof and their application as pharmaceuticals for the treatment of human disease. Methods of inhibition of FimH activity in a human subject are also provided for the treatment of diseases such as bacterial infection, Crohn's disease (CD) and Inflammatory Bowel Disease (IBD).
1. A method of treatment of a FimH-mediated disease in a human in need thereof, comprising administering to the human a therapeutically effective amount of a compound which is:
2. The method as recited in claim 1 , wherein said disease is a bacterial infection.
3. The method as recited in claim 2 , wherein said bacterial infection is an antibiotic-resistant bacterial infection.
4. The method as recited in claim 3 , wherein said compound is administered orally.
5. The method as recited in claim 4 , wherein said compound is administered as a tablet.
6. The method as recited in claim 4 , wherein said compound is administered as a capsule.
7. The method as recited in claim 2 , wherein said compound is administered orally.
8. The method as recited in claim 7 , wherein said compound is administered as a tablet.
9. The method as recited in claim 7 , wherein said compound is administered as a capsule.
10. The method as recited in claim 1 , wherein said disease is Crohn's disease (CD).
11. The method as recited in claim 1 , wherein said disease is Inflammatory Bowel Disease (IBD).
12. The method as recited in claim 1 , wherein said compound is administered orally.
13. The method as recited in claim 12 , wherein said compound is administered as a tablet.
14. The method as recited in claim 12 , wherein said compound is administered as a capsule.
15. A method of treatment of a FimH-mediated disease in a human in need thereof, comprising administering to the human a therapeutically effective amount of a compound which is:
wherein said disease is a bacterial infection and said bacterial infection is a urinary tract infection.
16. The method as recited in claim 15 , wherein said urinary tract infection is recurrent.
17. The method as recited in claim 15 , wherein said urinary tract infection is chronic.
18. The method as recited in claim 15 , wherein said compound is administered orally.
19. The method as recited in claim 18 , wherein said compound is administered as a tablet.
20. The method as recited in claim 18 , wherein said compound is administered as a capsule.